Yasuaki Tatsumi

Dr. Yasuaki Tatsumi

Aichi Gakuin University School of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2018 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
YTYasuaki Tatsumi
Yasuaki Tatsumi
AKAyako Kato
Ayako Kato
KSKazunori Sango
Kazunori Sango
THTatsuhito Himeno
Tatsuhito Himeno
MKMasaki Kondo
Masaki Kondo
Koichi KatoKoichi Kato
Koichi Kato
Aim/Introduction Recent studies advocate that omega‐3 polyunsaturated fatty acids (ω‐3 PUFAs) have direct antioxidative and anti‐inflammatory effects in the vasculature; however, the role of ω‐3 PUFAs in Schwann cells remains undetermined. Materials and Methods Immortalized mouse Schwann (IMS32) cells were incubated with the ω‐3 PUFAs docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). The mRNA levels of several antioxidant enzymes [heme oxygenase‐1 (Ho‐1), NAD(P)H quinone oxidoreductase 1 (Nqo1), catalase (Cat), superoxide dismutase (Sod), and glutathione peroxidase (Gpx)] were identified using real‐time reverse transcription polymerase chain reaction (RT‐PCR). Ho‐1 and Nqo1 protein levels were evaluated using Western blotting. NF‐E2‐related factor 2 (Nrf2) of the nuclear fraction was also quantified using Western blotting. Catalase activity and glutathione (GSH) contents were determined by colorimetric assay kits. Nrf2 promoter‐luciferase activity was evaluated by a dual luciferase assay system. Results Treatment with tert‐butyl hydroperoxide (tBHP) decreased cell viability dose‐dependently. DHA or EPA pretreatment significantly alleviated tBHP‐induced cytotoxicity. DHA or EPA increased the mRNA levels of Ho‐1, Nqo1, and Cat dose‐dependently. Ho‐1 protein level, catalase activity, Nrf2 promoter‐luciferase activity, and intracellular GSH contents were significantly increased by DHA and EPA. Conclusions These findings indicate that DHA and EPA can induce Ho‐1 and catalase via Nrf2, thus protecting Schwann cells against oxidative stress. ω‐3 PUFAs appear to exert their neuroprotective effect by increasing defense mechanisms against oxidative stress in diabetic neuropathies.

14 March 2016 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Shinsaku ImashukuShinsaku Imashuku
Shinsaku Imashuku
HMHideki Muramatsu
Hideki Muramatsu
TSTakashi Sugihara
Takashi Sugihara
YOYusuke Okuno
Yusuke Okuno
XWXinan Wang
Xinan Wang
Hitoshi KannoHitoshi Kanno
Hitoshi Kanno

Verified
Journal Article
Open access
PDF file
YTYasuaki Tatsumi
Yasuaki Tatsumi
AKAyako Kato
Ayako Kato
NNNaoko NIIMI
Naoko NIIMI
HYHideji Yako
Hideji Yako
THTatsuhito Himeno
Tatsuhito Himeno
Koichi KatoKoichi Kato
Koichi Kato
Autophagy is the process by which intracellular components are degraded by lysosomes. It is also activated by oxidative stress; hence, autophagy is thought to be closely related to oxidative stress, one of the major causes of diabetic neuropathy. We previously reported that docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) induced antioxidant enzymes and protected Schwann cells from oxidative stress. However, the relationship between autophagy and oxidative stress-induced cell death in diabetic neuropathy has not been elucidated. Treatment with tert-butyl hydroperoxide (tBHP) decreased the cell survival rate, as measured by an MTT assay in immortalized Fischer rat Schwann cells 1 (IFRS1). A DHA pretreatment significantly prevented tBHP-induced cytotoxicity. tBHP increased autophagy, which was revealed by the ratio of the initiation markers, AMP-activated protein kinase, and UNC51-like kinase phosphorylation. Conversely, the DHA pretreatment suppressed excessive tBHP-induced autophagy signaling. Autophagosomes induced by tBHP in IFRS1 cells were decreased to control levels by the DHA pretreatment whereas autolysosomes were only partially decreased. These results suggest that DHA attenuated excessive autophagy induced by oxidative stress in Schwann cells and may be useful to prevent or reduce cell death in vitro. However, its potentiality to treat diabetic neuropathy must be validated in in vivo studies.

17 August 2011 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
TMTakashi Maeda
Takashi Maeda
TNTsuyoshi Nakamaki
Tsuyoshi Nakamaki
BSBungo Saito
Bungo Saito
HNHidetoshi Nakashima
Hidetoshi Nakashima
HAHirotsugu Ariizumi
Hirotsugu Ariizumi
STShigeru Tomoyasu
Shigeru Tomoyasu

7 June 2018 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
YTYasuaki Tatsumi
Yasuaki Tatsumi
AKAyako Kato
Ayako Kato
KKKoichi Kato
Koichi Kato
HHHisao Hayashi
Hisao Hayashi

15 August 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
YTYasuaki Tatsumi
Yasuaki Tatsumi
KSKatsuhisa Sakai
Katsuhisa Sakai
YTYasumichi Toki
Yasumichi Toki
KIKatsuya Ikuta
Katsuya Ikuta
KTKazuhisa Takami
Kazuhisa Takami
Juvenile hemochromatosis (JH), type 2A hemochromatosis, is a rare autosomal recessive disorder of systemic iron overload due to homozygous mutations of HJV (HFE2), which encodes hemojuvelin, an essential regulator of the hepcidin expression, causing liver fibrosis, diabetes, and heart failure before 30 years of age, often with fatal outcomes. We report two Japanese sisters of 37 and 52 years of age, with JH, who showed the same homozygous HJV I281T mutation and hepcidin deficiency and who both responded well to phlebotomy on an outpatient basis. When all reported cases of JH with homozygous HJV mutations in the relevant literature were reviewed, we found—for the first time—that JH developed in females and males at a ratio of 3:2, with no age difference in the two groups. Furthermore, we found that the age of onset of JH may depend on the types of HJV mutations. In comparison to patients with the most common G320V/G320V mutation, JH developed earlier in patients with L101P/L101P or R385X/R385X mutations and later in patients with I281T/I281T mutations.